Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study to Evaluate Fractional Collagen Synthesis Within Keloid Scars and Identify Biomarkers of Keloid Scars

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01978301
Recruitment Status : Terminated (Temporary hold on recruitment during staff changes at the site)
First Posted : November 7, 2013
Last Update Posted : May 15, 2017
Sponsor:
Information provided by (Responsible Party):
GlaxoSmithKline

Brief Summary:
This is a 3-arm randomised clinical enabling study, with no investigational product. Keloid patients who are scheduled for surgical excision of one or more keloid scars (up to nine) will be recruited to the study. The aim is to investigate how collagen synthesis within keloid scars is affected by the current approved steroid treatment for keloids, triamcinolone acetonide (TAC). The primary endpoint will be fractional collagen synthesis in keloids which have received intra-lesional injections of TAC, placebo or no treatment prior to their removal. Fractional collagen synthesis will be determined using an established isotope/mass spectrometric technique which measures levels of deuterium incorporation into collagen following administration of heavy water to the subject. In addition; keloid tissue samples will be evaluated post surgery to identify further biomarkers of extracellular matrix synthesis and degradation for application in future clinical studies. Subjects will complete a screening visit and will then be randomised to receive three intra-lesional injections of TAC or placebo, or no treatment, at an interval of 2-3 weeks. Subjects will be randomised to different treatment sequences depending on the number of keloids they have scheduled for surgery, in such a way that subjects with multiple keloids will receive different arms of study treatment in their different keloids. Planned surgery for removal of their keloid(s) will be performed at week 6-8. All subjects will receive daily heavy water (Deuterium oxide) administration (twice daily or thrice daily as directed), with the first dose being taken at the Week 2 clinic visit and the final dose being taken on the day prior to surgery. A follow-up visit will be conducted at 1-4 weeks post-surgery.

Condition or disease Intervention/treatment Phase
Fibrosis Drug: Triamcinolone acetonide Drug: Placebo Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 9 participants
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Diagnostic
Official Title: A Randomised Open Label Placebo Controlled Study to Evaluate Fractional Collagen Synthesis in Keloids and Identify Biomarkers of Keloid Biology for Potential Application in Future Clinical Trials
Actual Study Start Date : April 15, 2014
Actual Primary Completion Date : February 5, 2015
Actual Study Completion Date : February 5, 2015

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Scars

Arm Intervention/treatment
Active Comparator: Triamcinolone acetonide
Subjects will receive three intra-lesional injections of triamcinolone acetonide in their qualifying keloid(s), at 2-3 weeks intervals, according to their assigned treatment sequence
Drug: Triamcinolone acetonide
Triamcinolone acetonide will be administered as intra-lesional injection in the keloid(s).

Placebo Comparator: Placebo
Subjects will receive three intra-lesional injections of placebo in their qualifying keloid(s), at 2-3 weeks intervals, according to their assigned treatment sequence.
Drug: Placebo
Placebo will supplied as commercial injectable saline, and will be administered as intra-lesional injection in the keloid(s).

No Intervention: No treatment
Keloid(s) assigned 'No Treatment' will not receive any treatment.



Primary Outcome Measures :
  1. Fractional synthesis of collagen in keloid scars [ Time Frame: Week 6-8 ]
    Post surgical excision of keloids, tissue samples will be obtained by snap frozen biopsies. Fractional synthesis of collagen (that is, the fraction of the collagen that is newly synthesised during the labelling period) will be determined using mass spectrometry which measures the levels of deuterium incorporation into hydroxyproline or alanine in the collagen from the excised tissue samples, following administration of heavy water (Deuterium oxide) to the subject


Secondary Outcome Measures :
  1. Keloid scar volume before first dose and immediately prior to surgery [ Time Frame: Day 1 and Week 6-8 ]
    For each keloid under evaluation, the keloid volume will be measured using three-dimensional (3D) photography

  2. Keloid scar surface area before first dose and immediately prior to surgery [ Time Frame: Day 1 and Week 6-8 ]
    For each keloid under evaluation, the keloid surface area will be measured using 3D photography

  3. Keloid scar length and height before first dose and immediately prior to surgery [ Time Frame: Day 1 and Week 6-8 ]
    For each keloid under evaluation, the keloid length and height will be measured using 3D photography

  4. Keloid scar vascularity before first dose and immediately prior to surgery [ Time Frame: Day 1 and Week 6-8 ]
    For each keloid under evaluation, the keloid vascularity will be measured by laser Doppler



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Subjects have at least one keloid scar scheduled for removal as part of their normal course of treatment
  • Males or females aged between 18 and 55 years of age inclusive, at the time of signing the informed consent.
  • A female subject is eligible to participate if she is of: Child-bearing potential with negative pregnancy test as determined by urine human chorionic gonadotropin (hCG) test at screening, AND; agrees not to become pregnant during the course of the study and for at least 1 month after completion of heavy water consumption; OR is of non child-bearing potential
  • Male subjects must agree not to father a child during the study and for at least 1 month after completion of heavy water consumption.
  • Capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the consent form

Exclusion Criteria:

  • Keloids to be randomised must not have received steroid treatment for at least two months prior to screening.
  • Evidence of other skin conditions or scarring in the region of keloid scaring (including but not limited to: hypertrophic scars, eczema, psoriasis, etc.) unless the Investigator, in consultation with the GSK medical monitor, agree that the condition is unlikely to introduce additional risk factors and will not interfere with the study procedures.
  • Current or chronic history of liver disease, or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones).
  • History of regular alcohol consumption that could preclude safe completion of the study.
  • History of sensitivity to corticosteroids or history of drug or other allergy that, in the opinion of the investigator or GlaxoSmithKline (GSK) Medical Monitor, contraindicates their participation.
  • Subjects currently receiving oral corticosteroids.
  • Subjects with a recent history of tuberculosis (TB) (within last three years).
  • Evidence or recent history (past two weeks) of any infection (viral, bacterial, fungal, protozoan, or helminthic).
  • History of recurrent fungal infection.
  • Lactating females.
  • The subject has participated in a clinical trial and has received an investigational product within the following time period prior to the first dosing day in the current study: 30 days, 5 half-lives or twice the duration of the biological effect of the investigational product (whichever is longer).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01978301


Locations
Layout table for location information
United Kingdom
GSK Investigational Site
London, United Kingdom, E1 2AT
Sponsors and Collaborators
GlaxoSmithKline
Investigators
Layout table for investigator information
Study Director: GSK Clinical Trials GlaxoSmithKline
Layout table for additonal information
Responsible Party: GlaxoSmithKline
ClinicalTrials.gov Identifier: NCT01978301    
Other Study ID Numbers: 117287
First Posted: November 7, 2013    Key Record Dates
Last Update Posted: May 15, 2017
Last Verified: May 2017
Keywords provided by GlaxoSmithKline:
triamcinolone acetonide (TAC)
heavy water
fibrosis
deuterium
collagen degradation
collagen synthesis
Keloid
patient
Additional relevant MeSH terms:
Layout table for MeSH terms
Keloid
Fibrosis
Pathologic Processes
Collagen Diseases
Connective Tissue Diseases
Cicatrix
Triamcinolone
Triamcinolone Acetonide
Triamcinolone hexacetonide
Triamcinolone diacetate
Anti-Inflammatory Agents
Glucocorticoids
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Immunosuppressive Agents
Immunologic Factors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action